SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Adaptimmune Therapeutics plc (ADAP) .
本页证实的标准:
- VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+5735.1%).
- 分析师共识目标价 $2.83 (+5735.1% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 52/100 其中 3/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✗
健康
33/100
Debt-to-Equity & liquidity
→ Health
估值概览 — ADAP
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.07
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.28
每股账面价值$0.00
每股营收$0.71
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$2.83 (+5735.1%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2015 |
$-0.60 |
$10.72M |
$-21.59M |
-201.4% |
| 2016 |
$-1.02 |
$14.2M |
$-71.58M |
-504.1% |
| 2017 |
$-0.78 |
$37.83M |
$-70.14M |
-185.4% |
| 2018 |
$-0.96 |
$59.51M |
$-95.51M |
-160.5% |
| 2019 |
$-1.32 |
$1.12M |
$-137.17M |
-12225% |
| 2020 |
$-0.90 |
$3.96M |
$-130.09M |
-3286.8% |
| 2021 |
$-1.02 |
$6.15M |
$-158.09M |
-2571% |
| 2022 |
$-1.02 |
$27.15M |
$-165.46M |
-609.5% |
| 2023 |
$-0.57 |
$60.28M |
$-113.87M |
-188.9% |
| 2024 |
$-0.28 |
$178.03M |
$-70.81M |
-39.8% |
